Hunt and Hess scale
Hunt and Hess scale is a grading system used to classify the severity of a subarachnoid hemorrhage (SAH) based on the patient's clinical condition. The scale was introduced in 1968 by William Hunt and Robert Hess as a way to assess the prognosis of patients with SAH and to help guide treatment decisions. The Hunt and Hess scale ranges from Grade I, indicating a mild condition, to Grade V, which signifies a severe condition with a poor prognosis.
Grades
The Hunt and Hess scale includes the following grades:
- Grade I: Asymptomatic or minimal headache and slight nuchal rigidity. No neurological deficit other than cranial nerve palsy.
- Grade II: Moderate to severe headache, nuchal rigidity, no neurological deficit other than cranial nerve palsy.
- Grade III: Drowsiness, confusion, or mild focal deficit.
- Grade IV: Stupor, moderate to severe hemiparesis, possibly early decerebrate rigidity, and vegetative disturbances.
- Grade V: Deep coma, decerebrate rigidity, moribund appearance.
Clinical Application
The Hunt and Hess scale is primarily used by healthcare professionals to quickly assess the severity of a subarachnoid hemorrhage and to make initial decisions about the best course of treatment. It is an important tool in the management of SAH patients, as it helps to predict outcomes and guide interventions. The scale is also used in research settings to stratify patients and to compare outcomes across different treatment modalities.
Limitations
While the Hunt and Hess scale is widely used, it has some limitations. The scale is somewhat subjective, as it relies on clinical judgment to assess the severity of symptoms. This can lead to variability in grading between different observers. Additionally, the scale does not take into account factors such as age, the presence of other medical conditions, or the size and location of the hemorrhage, which can also affect prognosis.
See Also
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
